David Bloom discussed on Larry King.... www.PreventDVT.org....

[HysteryDiagnosis]

www.PreventDVT.org

DVT occurs when a blood clot forms in a deep vein, usually in the lower limbs. A complication of DVT, pulmonary embolism, can occur when a fragment of a blood clot breaks loose from the wall of the vein and migrates to the lungs, where it blocks a pulmonary artery or one of its branches.

If you are off your feet for a while due to cancer or certain heart or respiratory diseases, talk to your doctor or click here for more details on DVT risk factors.

AND WHAT THEY WILL NOT TELL YOU ABOUT IT.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15497024

1: Clin Appl Thromb Hemost. 2004 Oct;10(4):373-7. Related Articles, Links

Prevention of venous thrombosis and thrombophlebitis in long-haul flights with pycnogenol.

Belcaro G, Cesarone MR, Rohdewald P, Ricci A, Ippolito E, Dugall M, Griffin M, Ruffini I, Acerbi G, Vinciguerra MG, Bavera P, Di Renzo A, Errichi BM, Cerritelli F.

Department of Biomedical Sciences, Irvine2 Vascular Lab, G D'Annunzio University and San Valentino Vascular Screening Project (Pe), Faculty of Motory Sciences, L'Aquila University, Italy. [e-mail]

The aim of this study was to evaluate the occurrence of deep venous thrombosis (DVT) and superficial vein thrombosis (SVT) and its prophylaxis with an oral anti-edema and antithrombotic agent (Pycnogenol, Horphag, Research Management SA, Geneva, Switzerland) in long-haul flights, in subjects at moderate to high-risk of DVT and SVT. The study pre-included 244 pre-selected subjects; 211 were included (33 were excluded for several reasons due to logistic problems) and 198 completed the study; 13 subjects were lost for follow-up at the end of the flight, all for non-medical problems (i.e., for difficult connections).

All subjects were scanned within 90 minutes before the flight and within 2 hours after disembarking. Subjects were supplemented with 100 mg Pycnogenol per capsule. Treatment subjects received two capsules between 2 and 3 hours before flights with 250 mL of water; two capsules were taken 6 hours later with 250 mL of water and one capsule the next day. The control group received comparable placebo at the same intervals.

The flight duration was on average 8 hours and 15 minutes (SD 55 min) (range, 7.45-12.33). In the control group there were five thrombotic events (one DVT and four superficial thromboses) while only nonthrombotic, localized phlebitis was observed in the Pycnogenol group (5.15% vs. no events; p<0.025). The ITT (intention to treat) analysis detects 13 failures in the control group (eight lost to follow up + five thrombotic events) of 105 subjects (12.4%) vs. five failures (4.7%; all lost, no thrombotic events) in the treatment group (p<0.025). No unwanted effects were observed.


In conclusion, this study indicates that Pycnogenol treatment was effective in decreasing the number of thrombotic events (DVT and SVT) in moderate-to-high risk subjects, during long-haul flights.
PMID: 15497024

[HysteryDiagnosis]

1. More risk factors..... you won't be told about. Did you ever wonder

why most of the studies that show the relationship between naturally ocurring bodily chemicals/antioxidants are foreign?? I don't.. I know who runs things here.


http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11705822

1: Circulation. 2001 Nov 13;104(20):2442-6. Related Articles, Links

Low plasma levels of vitamin B(6) are independently associated with a heightened risk of deep-vein thrombosis.

Cattaneo M, Lombardi R, Lecchi A, Bucciarelli P, Mannucci PM.

Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine, IRCCS Ospedale Maggiore, University of Milano, Milano, Italy. [e-mail]

BACKGROUND: Elevated plasma levels of total homocysteine (tHcy) before and after an oral methionine load (PML) are associated with an elevated risk of deep-vein thrombosis (DVT). We investigated whether plasma levels of B vitamins that are involved in Hcy metabolism are associated with an elevated risk of DVT. METHODS AND RESULTS: We compared 397 cases with previous DVT with 585 matched healthy controls.

The plasma levels of folate, vitamin B(12), vitamin B(6,), and fasting and PML tHcy were measured. The ORs for DVT associated with high (>95th percentile) fasting levels and PML increases of tHcy were 2.1 (95% CI, 1.2 to 3.4) and 2.4 (95% CI, 1.5 to 3.9) after adjustment for established risk factors for DVT. Fasting plasma levels and PML increases in tHcy correlated negatively with vitamin levels.

The crude OR for folate levels in the lowest quartile compared with the highest was 1.5 (95% CI, 1.1 to 2.1), and that for B(6) levels in the lowest and second quartiles compared with the highest was 1.5 (95% CI, 1.0 to 2.1). However, after adjustment for established risk factors and fasting and PML tHcy, the ORs for B(6) levels in the lowest and second quartiles only remained statistically significant (lowest quartile: OR, 1.8; 95% CI, 1.2 to 2.8; second quartile, OR, 1.9; 95% CI, 1.3 to 2.9).

CONCLUSIONS: High fasting and PML tHcy and low vitamin B(6) plasma levels are associated with an elevated risk for DVT independently of established risk factors for DVT. The association of low vitamin B(6) levels with the risk for DVT is independent of fasting and PML tHcy levels.

PMID: 11705822